title: [Acute mixed lineage leukemia showing resistance to AML and ALL therapy].
abstract: A 51-year-old female was who admitted complaining of cough and slight fever and lower limb petechia. The laboratory examinations revealed leukocytosis (49,400/microliters) with blasts (71%) in the peripheral blood. The NCC was 30 x 10(4)/microliters with 84.8% blasts in the bone marrow. Myeloperoxidase staining was positive for 6% of blasts. Auer rods were not seen in some blasts. Thus, acute myeloblastic leukemia (M1) was diagnosed according to FAB classification. In the peripheral blood, 43.3% of blasts expressed CD19, 10.3% of blasts expressed CD20 and 55.6% of blasts expressed CD33 on admission. Though she received two courses of DCMP according to the DCMP-85 protocol, and one combined course of mitoxantrone, etoposide, and Ara-C. The NCC was 20.0 x 10(4)/microliters with 70% blasts in the bone marrow. CD19 was expressed by 72.4% of blasts and 35.0% expressed CD20. The ALL-90 protocol was started, but remission was not achieved. Thus this case was considered to be acute mixed lineage leukemia.
authors.affiliation: Third Department of Internal Medicine, Nihon University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Kawashima
authors.forename: Y
authors.initials: Y
authors.lastname: Iizuka
authors.forename: W
authors.initials: W
authors.lastname: Kondou
authors.forename: H
authors.initials: H
authors.lastname: Hirota
authors.forename: Y
authors.initials: Y
authors.lastname: Okuyama
authors.forename: M
authors.initials: M
authors.lastname: Kanou
authors.forename: S
authors.initials: S
authors.lastname: Ichii
authors.forename: J
authors.initials: J
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: T
authors.initials: T
authors.lastname: Sawada
mesh_terms: D015703:Antigens, CD / Q000032:analysis*; D018941:Antigens, CD19; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D063268:Sialic Acid Binding Ig-like Lectin 3
chemical_list: D015703:Antigens, CD; D018941:Antigens, CD19; D000944:Antigens, Differentiation, B-Lymphocyte; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3